A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)
NCT00927511
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
104
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Fulvestrant
Sponsor
Regina Elena Cancer Institute
Collaborators
[object Object]